We are live on ! Find out more

IPHA

Innate Pharma

IPHA

Market cap $190M

1.70 USD

0.00

0%

At close Updated Sep 25, 4:00 PM EDT

1 day

0%

5 days

-8.6%

1 month

-25.11%

3 months

-5.03%

6 months

32.81%

Year to date

-6.59%

1 year

-6.59%

5 years

-75.99%

10 years

-71.9%

About: Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Employees: 163

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 23.5%

Neutral 76.5%

Negative 0%

Zacks Investment Research

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma Q2 Earnings Call Highlights

Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab.

Innate Pharma Q2 Earnings Call Highlights

Innate Pharma Reports First Half 2026 Business Update and Financial Results

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2026. The consolidated financial statements are attached to this press release. “2026 continues to be an important year of execution for Innate, marked by our strategic partnership with Sobi and the strengthening of our financial position,” said Jonathan Dickinson, CEO of Innate P.

Innate Pharma Reports First Half 2026 Business Update and Financial Results

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions. As announced on August 10, 2026, Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma. Transaction closing triggers the USD 75.

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026. Participants in the call will be: Jonathan Dickinson, Chief Executive Officer Markus Jensen, Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Op.

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor meetings at the following conference: H.C. Wainwright 28th Annual Global Investment Conference Dates: September 14–16, 2026 Location: New York, United States Fireside.

Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Innate Pharma Secures €30M, Extends Cash Runway Into 2028

Innate Pharma NASDAQ: IPHA said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs and its preclinical antibody-drug conjugate, or ADC, portfolio.

Innate Pharma Secures €30M, Extends Cash Runway Into 2028

Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript

Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript

Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript

Innate Pharma Announces Conference Call and Webcast

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.

Innate Pharma Announces Conference Call and Webcast

See News Rankings

Price charts implemented using Lightweight Charts™